S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
The Next Big Crisis Is Here (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
The Next Big Crisis Is Here (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
The Next Big Crisis Is Here (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
The Next Big Crisis Is Here (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
The Next Big Crisis Is Here (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
The Next Big Crisis Is Here (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
The Next Big Crisis Is Here (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
The Next Big Crisis Is Here (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Stock Forecast, Price & News

$156.66
+2.89 (+1.88%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$153.53
$156.80
50-Day Range
$149.93
$160.47
52-Week Range
$125.36
$169.98
Volume
345,445 shs
Average Volume
456,687 shs
Market Capitalization
$9.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$202.55

Jazz Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.90 Rating Score
Upside/​Downside
29.3% Upside
$202.55 Price Target
Short Interest
Healthy
4.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
1.08mentions of Jazz Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.82 M Sold Last Quarter
Proj. Earnings Growth
6.13%
From $15.18 to $16.11 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.64 out of 5 stars

Medical Sector

137th out of 1,055 stocks

Pharmaceutical Preparations Industry

56th out of 518 stocks


JAZZ stock logo

About Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
H.C. Wainwright Reaffirms Their Buy Rating on Novan (NOVN)
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Company Calendar

Last Earnings
11/09/2022
Today
1/31/2023
Next Earnings (Estimated)
3/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
3,200
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$202.55
High Stock Price Forecast
$225.00
Low Stock Price Forecast
$187.00
Forecasted Upside/Downside
+29.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Net Income
$-329,670,000.00
Pretax Margin
-2.17%

Debt

Sales & Book Value

Annual Sales
$3.09 billion
Cash Flow
$23.11 per share
Book Value
$64.51 per share

Miscellaneous

Free Float
60,195,000
Market Cap
$9.86 billion
Optionable
Optionable
Beta
0.74

Social Links


Key Executives

  • Mr. Bruce C. CozaddMr. Bruce C. Cozadd (Age 59)
    Co-Founder, Chairman & CEO
    Comp: $2.27M
  • Mr. Daniel N. Swisher Jr. (Age 60)
    Pres & COO
    Comp: $1.27M
  • Ms. Renee D. Gala (Age 51)
    Exec. VP & CFO
    Comp: $1.03M
  • Dr. Robert Iannone M.D. (Age 56)
    Exec. VP and Global Head of R&D
    Comp: $983.25k
  • Ms. Patricia Carr (Age 52)
    Sr. VP & Chief Accounting Officer
  • Dr. Finbar Larkin Ph.D. (Age 65)
    Sr. VP of Technical Operations
  • Ms. Andrea N. Flynn Ph.D.
    VP & Head of Investor Relations
  • Ms. Neena M. Patil J.D.Ms. Neena M. Patil J.D. (Age 48)
    Exec. VP & Chief Legal Officer
  • Dr. George Christopher Eliades Ph.D. (Age 52)
    Sr. VP of Corp. Devel. & Chief Transformation Officer
  • Ms. Heidi Manna (Age 51)
    Sr. VP & Chief HR Officer













JAZZ Stock - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price forecast for 2023?

10 brokerages have issued twelve-month price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price forecasts range from $187.00 to $225.00. On average, they expect the company's stock price to reach $202.55 in the next year. This suggests a possible upside of 29.3% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 on January 1st, 2023. Since then, JAZZ shares have decreased by 1.7% and is now trading at $156.66.
View the best growth stocks for 2023 here
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its quarterly earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported $4.53 EPS for the quarter, beating analysts' consensus estimates of $4.35 by $0.18. The specialty pharmaceutical company had revenue of $940.65 million for the quarter, compared to analysts' expectations of $939.88 million. Jazz Pharmaceuticals had a negative net margin of 0.52% and a positive trailing twelve-month return on equity of 30.71%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of $17.20-$17.85 for the period, compared to the consensus estimate of $17.41. The company issued revenue guidance of $3.60 billion-$3.70 billion, compared to the consensus revenue estimate of $3.65 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

What is Jazz Pharmaceuticals' stock symbol?

Jazz Pharmaceuticals trades on the NASDAQ under the ticker symbol "JAZZ."

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.40%), Sumitomo Mitsui Trust Holdings Inc. (0.28%), Allspring Global Investments Holdings LLC (0.20%), New York State Common Retirement Fund (0.17%), Nepsis Inc. (0.13%) and Calamos Wealth Management LLC (0.08%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kim Sablich, Mark Douglas Smith, Michael Patrick Miller, Neena M Patil, Patricia Carr, Patrick G Enright, Paul L Berns, Peter Gray, Renee D Gala, Robert Iannone, Samantha Pearce and Seamus Mulligan.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jazz Pharmaceuticals' stock price today?

One share of JAZZ stock can currently be purchased for approximately $156.66.

How much money does Jazz Pharmaceuticals make?

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a market capitalization of $9.86 billion and generates $3.09 billion in revenue each year. The specialty pharmaceutical company earns $-329,670,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis.

How many employees does Jazz Pharmaceuticals have?

The company employs 3,200 workers across the globe.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
How can I contact Jazz Pharmaceuticals?

Jazz Pharmaceuticals' mailing address is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. The official website for the company is www.jazzpharma.com. The specialty pharmaceutical company can be reached via phone at (531) 634-7800, via email at investorinfo@jazzpharma.com, or via fax at 353-1634-7850.

This page (NASDAQ:JAZZ) was last updated on 2/1/2023 by MarketBeat.com Staff